Skip to main content

Advertisement

SpringerLink
Log in

Use of oral contraceptives and postmenopausal hormone replacement: Evidence on risk of stroke

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Estrogen and progesterone affect endothelial function, coagulation factors, platelet function, lipids, and inflammation and have neuroprotective effects in experimental animals. Oral contraceptives containing low-dose estrogen increase the risk of ischemic stroke, but the absolute risk is low. Risk factors further increasing the risk of stroke in users of oral contraceptives include smoking, hypertension, diabetes, hyperlipidemia, migraine with aura, and thrombophilia. Progestin-only contraceptives do not increase the risk of stroke and are preferable in women with cerebrovascular disease or risk factors. Hormone replacement therapy (HRT) with estrogen alone or combined with progesterone increases the risk of ischemic stroke by 40% with no effect on hemorrhagic stroke. Stroke risk increases with the dose of estrogen. The time between menopause and the initiation of HRT does not influence ischemic stroke risk. The only indication for HRT is the treatment of vasomotor symptoms; if needed for this purpose, the lowest dose of estrogen should be used for the shortest possible duration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Harman SM: Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med 2006, 3:254–269.

    Article  PubMed  Google Scholar 

  2. Bushnell CD: Oestrogen and stroke in women: assessment of risk. Lancet Neurol 2005, 4:743–751.

    Article  PubMed  CAS  Google Scholar 

  3. Duckles SP, Krause DN: Cerebrovascular effects of oestrogen: multiplicity of action. Clin Exp Pharmacol Physiol 2007, 34:801–808.

    Article  PubMed  CAS  Google Scholar 

  4. Billeci A, Paciaroni M, Caso V, Agnelli G: Hormone replacement therapy and stroke. Curr Vasc Pharmacol 2008, 6:112–123.

    Article  PubMed  CAS  Google Scholar 

  5. Wierman ME, Kohrt WM: Vascular and metabolic effects of sex steroids: new insights into clinical trials. Reprod Sci 2007, 14:300–314.

    Article  PubMed  CAS  Google Scholar 

  6. Manson JE, Bassuk SS, Harman S, et al.: Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006, 13:139–147.

    Article  PubMed  Google Scholar 

  7. Miller VM, Jayachandran M, Hashimoto K, et al.: Estrogen, inflammation, and platelet phenotype. Gend Med 2008, 5(Suppl 1):S91–S102.

    Article  PubMed  Google Scholar 

  8. The ESHRE Capri Workshop Group: Hormones and cardiovascular health in women. Hum Reprod Update 2006, 12:483–497.

    Article  Google Scholar 

  9. Hodis HN, Mack WJ: Postmenopausal hormone therapy in clinical perspective. Menopause 2007, 14:944–957.

    Article  PubMed  Google Scholar 

  10. Kemmeren JM, Tanis BC, van den Bosch MA, et al.: Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002, 33:1202–1208.

    Article  PubMed  Google Scholar 

  11. Stein DG, Wright DW, Kellermann AL: Does progesterone have neuroprotective properties? Ann Emerg Med 2008, 51:164–172.

    Article  PubMed  Google Scholar 

  12. Chan WS, Ray J, Wai EK, et al.: Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004, 164:741–747.

    Article  PubMed  Google Scholar 

  13. Baillargeon JP, McClish DK, Essah PA, Nestler JE: Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005, 90:3863–3870.

    Article  PubMed  CAS  Google Scholar 

  14. Gillum LA, Mamidipudi SK, Johnston SC: Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000, 284:72–78.

    Article  PubMed  CAS  Google Scholar 

  15. MacClellan LR, Giles W, Cole J, et al.: Probable migraine with visual aura and risk of ischemic stroke: The Stroke Prevention in Young Women Study. Stroke 2007, 38:2438–2445.

    Article  PubMed  Google Scholar 

  16. Slooter AJ, Rosendaal FR, Tanis BC, et al.: Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005, 3:1213–1217.

    Article  PubMed  CAS  Google Scholar 

  17. Martinelli I, Battaglioli T, Burgo I, et al.: Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006, 91:844–847.

    PubMed  Google Scholar 

  18. Pezzini A, Grassi M, Iacoviello L, et al.: Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007, 78:271–276.

    Article  PubMed  CAS  Google Scholar 

  19. Pruissen DM, Slooter AJ, Rosendaal FR, et al.: Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008, 111:1282–1286.

    Article  PubMed  CAS  Google Scholar 

  20. ACOG Committee on Practice Bulletins-Gynecology: ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006, 107:1453–1472.

    Google Scholar 

  21. Goldstein LB, Adams R, Alberts MJ, et al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006, 37:1583–1633.

    PubMed  Google Scholar 

  22. Rosamond W, Flegal K, Furie K, et al.: Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25–e146.

    Article  PubMed  Google Scholar 

  23. Bushnell CD: Hormone replacement therapy and stroke: the current state of knowledge and directions for future research. Semin Neurol 2006, 26:123–130.

    Article  PubMed  Google Scholar 

  24. Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243–1249.

    Article  PubMed  CAS  Google Scholar 

  25. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al.: Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation 2006, 113:2425–2434.

    Article  PubMed  CAS  Google Scholar 

  26. The Women’s Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative Randomized Controlled Trial. JAMA 2004, 291:1701–1712.

    Article  Google Scholar 

  27. Wassertheil-Smoller S, Hendrix S, Limacher M, et al., for the WHI Investigators: Effect of estrogen plus progestin on stroke in postmenopausal women: The Women’s Health Initiative: a randomized trial. JAMA 2003, 289:2673–2684.

    Article  PubMed  CAS  Google Scholar 

  28. Rossouw JE, Prentice RL, Manson JE, et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465–1477.

    Article  PubMed  CAS  Google Scholar 

  29. Manson JE, Allison MA, Rossouw JE, et al.: Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356:2591–2602.

    Article  PubMed  CAS  Google Scholar 

  30. Kooperberg C, Cushman M, Hsia J, et al.: Can biomarkers identify women at increased stroke risk? The Women’s Health Initiative Hormone Trials. PLoS Clin Trials 2007, 2:E28.

    Article  PubMed  Google Scholar 

  31. Bath PMW, Gray LJ: Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005, 330:342.

    Article  PubMed  Google Scholar 

  32. Heiss G, Wallace R, Anderson GL, et al.: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008, 299:1036–1045.

    Article  PubMed  CAS  Google Scholar 

  33. Grodstein F, Manson JE, Stampfer MJ, Rexrode K: Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008, 168:861–866.

    Article  PubMed  CAS  Google Scholar 

  34. Umland EM: Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008, 14(3 Suppl):S14–S19.

    Google Scholar 

  35. Bushnell CD: Stroke and the female brain. Nat Clin Pract Neurol 2008, 4:22–33.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, 2 RCP, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA

    Patricia H. Davis

Authors
  1. Patricia H. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia H. Davis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, P.H. Use of oral contraceptives and postmenopausal hormone replacement: Evidence on risk of stroke. Curr Treat Options Neurol 10, 468–474 (2008). https://doi.org/10.1007/s11940-008-0049-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-008-0049-2

Keywords

Search

Navigation